Stiripentol directly attenuates immunosuppression of tumor-infiltrating myeloid cells to potentiate anti-PD-1 efficacy.
[BACKGROUND] Immune checkpoint blockade (ICB) therapy demonstrates significant efficacy across multiple malignancies, yet resistance remains prevalent.
APA
Xie Z, Wang K, et al. (2026). Stiripentol directly attenuates immunosuppression of tumor-infiltrating myeloid cells to potentiate anti-PD-1 efficacy.. BMC cancer, 26(1). https://doi.org/10.1186/s12885-026-15793-x
MLA
Xie Z, et al.. "Stiripentol directly attenuates immunosuppression of tumor-infiltrating myeloid cells to potentiate anti-PD-1 efficacy.." BMC cancer, vol. 26, no. 1, 2026.
PMID
41764441
Abstract
[BACKGROUND] Immune checkpoint blockade (ICB) therapy demonstrates significant efficacy across multiple malignancies, yet resistance remains prevalent. Recent studies have repositioned the clinically approved antiepileptic drug stiripentol (STP) as a potent lactate dehydrogenase A inhibitor that effectively disrupts tumor metabolic reprogramming, thereby reinstating tumor control. Despite its promising antineoplastic activity, the direct impact of STP on immune cells and its potential synergy with anti-PD-1 antibodies remain unexplored.
[METHODS] We used an orthotopic 4T1 breast cancer model to evaluate whether STP remodels the immunosuppressive tumor microenvironment and enhances anti-PD-1 efficacy. Tumor growth was monitored, and immune cell profiles in tumors and blood were analyzed by flow cytometry. Lactate levels and chemokine expression in tumor tissue were also assessed. In vitro, the effects of STP on 4T1 cell proliferation and lactate secretion, bone marrow-derived myeloid-derived suppressor cell (MDSC) differentiation and suppressive function, and macrophage polarization were evaluated.
[RESULTS] The combination of STP and anti-PD-1 synergistically suppressed 4T1 tumor growth, reduced the infiltration of immunosuppressive MDSCs and M2-like tumor-associated macrophages, and reactivated CD8⁺ T cells. STP inhibited 4T1 cell proliferation and lactate secretion in a concentration-dependent manner. Furthermore, STP directly reprogrammed MDSCs by inducing MHC II⁺ cell differentiation and attenuating their T cell suppressive capacity via downregulation of immunosuppressive genes. STP also drove M2-to-M1 macrophage repolarization. Importantly, STP exhibited no direct T cell-activating effects.
[CONCLUSIONS] Our work establishes STP as a potent remodeler of the immunosuppressive tumor microenvironment that synergizes with anti-PD-1 therapy, providing a novel strategy to overcome ICB resistance.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15793-x.
[METHODS] We used an orthotopic 4T1 breast cancer model to evaluate whether STP remodels the immunosuppressive tumor microenvironment and enhances anti-PD-1 efficacy. Tumor growth was monitored, and immune cell profiles in tumors and blood were analyzed by flow cytometry. Lactate levels and chemokine expression in tumor tissue were also assessed. In vitro, the effects of STP on 4T1 cell proliferation and lactate secretion, bone marrow-derived myeloid-derived suppressor cell (MDSC) differentiation and suppressive function, and macrophage polarization were evaluated.
[RESULTS] The combination of STP and anti-PD-1 synergistically suppressed 4T1 tumor growth, reduced the infiltration of immunosuppressive MDSCs and M2-like tumor-associated macrophages, and reactivated CD8⁺ T cells. STP inhibited 4T1 cell proliferation and lactate secretion in a concentration-dependent manner. Furthermore, STP directly reprogrammed MDSCs by inducing MHC II⁺ cell differentiation and attenuating their T cell suppressive capacity via downregulation of immunosuppressive genes. STP also drove M2-to-M1 macrophage repolarization. Importantly, STP exhibited no direct T cell-activating effects.
[CONCLUSIONS] Our work establishes STP as a potent remodeler of the immunosuppressive tumor microenvironment that synergizes with anti-PD-1 therapy, providing a novel strategy to overcome ICB resistance.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15793-x.
같은 제1저자의 인용 많은 논문 (5)
- METTL5 promotes fatty acid metabolism by modulating peroxisome to induce hepatocellular carcinoma recurrence after thermal ablation.
- Integrative multi-omics and radiogenomic profiling decodes NNK-related tumor remodeling and prognostic stratification in pancreatic cancer.
- A TtAgo-Driven Autocatalytic Circuit with Thermal-Enhanced Kinetics for One-Pot Nucleic Acid Detection.
- Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).
- Daidzein-engineered high-accumulation self-therapeutic nanoplatform drives androgen receptor degradation via ubiquitination-proteasome system to overcome enzalutamide resistance in castration-resistant prostate cancer.